Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14377638 | 0.83 | MGAM (0.42) | MGAMLMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL14413769 | 0.83 | MGAM (0.42) | MGAMLMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL7590412 | 0.77 | LMNA (0.46) | MGAMLMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL8486 | 0.76 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL599665 | 0.76 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL3851271 | 0.76 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL2848010 | 0.76 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL8718435 | 0.76 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL15754346 | 0.76 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL2316300 | 0.76 | LMNA (0.39) | MGAMLMNAL3MBTL1TDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175907-A1 | REMEDIES | Takara Shuzo Co, Ltd. (JP) | 2002-01-30 | — | — | EP | claimed |
| US-7816134-B2 | Method of extensive culture of antigen-specific cytotoxic T cells | TAKARA BIO INC. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7678368-B2 | Fucoidan-containing cosmetics | TAKARA BIO INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| EP-1234568-B1 | Use of fucoidan as effective hair restoring ingredient | TAKARA BIO INC (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20080166325-A1 | Method of extensive culture of antigen-specific cytotoxic T cells | SAGAWA HIROAKI | 2008-07-10 | — | — | US | disclosed |
| US-20060093566-A1 | Fucoidan-containing cosmetics | MIZUTANI SHIGETOSHI | 2006-05-04 | — | — | US | disclosed |
| US-20060051316-A1 | Remedy | TAKARA BIO INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1570845-A1 | REMEDY | TAKARA BIO INC. (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040115809-A1 | Method of extensive culture of antigen-specific cytotoxic t cells | TAKARA BIO INC. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1312670-A1 | METHOD OF EXTENSIVE CULTURE OF ANTIGEN-SPECIFIC CYTOTOXIC T CELLS | TAKARA BIO INC. (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-20030039670-A1 | Cosmetics | TAKARA BIO INC. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1234568-A1 | COSMETICS | Takara Shuzo Co, Ltd. (JP) | 2002-08-28 | — | — | EP | disclosed |
| EP-1175907-A1 | REMEDIES | Takara Shuzo Co, Ltd. (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030039670-A1 | Cosmetics | FUCA1, GLA, TYR | MGAM 679/4885LMNA 2088/4885L3MBTL1 3677/4885 |
| US-20060051316-A1 | Remedy | BMP2, BMP4, BMP1 | MGAM 41/4885LMNA 3595/4885L3MBTL1 3127/4885 |
| US-20060093566-A1 | Fucoidan-containing cosmetics | FUCA1, FUCA2, FUT5 | MGAM 756/4885LMNA 1966/4885L3MBTL1 3865/4885 |
| US-20080166325-A1 | Method of extensive culture of antigen-specific cytotoxic T cells | CD44, ALG1, CD47 | MGAM 182/4885LMNA 3986/4885L3MBTL1 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.